The footprint of kynurenine pathway in every cancer: a new target for chemotherapy
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The footprint of kynurenine pathway in every cancer: a new target for chemotherapy
Authors
Keywords
Kynurenine pathway, Cancer, IDO, Indoximod, Immune system, AHR
Journal
EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 896, Issue -, Pages 173921
Publisher
Elsevier BV
Online
2021-01-30
DOI
10.1016/j.ejphar.2021.173921
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Activation of the Kynurenine Pathway in Human Malignancies Can Be Suppressed by the Cyclin-Dependent Kinase Inhibitor Dinaciclib
- (2020) Christin Riess et al. Frontiers in Immunology
- PD-L1 and IDO1 expression and tumor-infiltrating lymphocytes in osteosarcoma patients: comparative study of primary and metastatic lesions
- (2020) Yu Toda et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Kynurenine 3-monooxygenase upregulates pluripotent genes through β-catenin and promotes triple-negative breast cancer progression
- (2020) Tzu-Ting Huang et al. EBioMedicine
- TDO Promotes Hepatocellular Carcinoma Progression
- (2020) Shanbao Li et al. OncoTargets and Therapy
- Indoximod opposes the immunosuppressive effects mediated by IDO and TDO via modulation of AhR function and activation of mTORC1
- (2020) Erik L. Brincks et al. Oncotarget
- Indoleamine 2,3-dioxygenase in melanoma progression and BRAF inhibitor resistance
- (2020) Silvana Sandri et al. PHARMACOLOGICAL RESEARCH
- Indoleamine 2,3-dioxygenase 1 and Programmed Cell Death-ligand 1 Co-expression Predicts Poor Pathologic Response and Recurrence in Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy
- (2019) Sha Zhou et al. Cancers
- H2S suppresses indoleamine 2, 3-dioxygenase 1 and exhibits immunotherapeutic efficacy in murine hepatocellular carcinoma
- (2019) Dan Yang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- IDO and intra-tumoral neutrophils were independent prognostic factors for overall survival for hepatocellular carcinoma
- (2019) Yan Wang et al. JOURNAL OF CLINICAL LABORATORY ANALYSIS
- Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
- (2019) Kyung Hae Jung et al. CLINICAL CANCER RESEARCH
- IDO1 and Kynurenine Pathway Metabolites Activate PI3K-Akt Signaling in the Neoplastic Colon Epithelium to Promote Cancer Cell Proliferation and Inhibit Apoptosis
- (2019) Kumar S. Bishnupuri et al. CANCER RESEARCH
- Salmonella-mediated therapy targeting indoleamine 2, 3-dioxygenase 1 (IDO) activates innate immunity and mitigates colorectal cancer growth
- (2019) Thuy Phan et al. CANCER GENE THERAPY
- Indoleamine 2, 3‐dioxygenase 1 promoter hypomethylation is associated with poor prognosis in patients with esophageal cancer
- (2019) Yuki Kiyozumi et al. CANCER SCIENCE
- Expression of Indoleamine 2,3-dioxygenase in erlotinib-treated patients with advanced pancreatic cancer: Translational results from a multi-center, randomized phase III trial
- (2019) S. Kruger et al. EUROPEAN JOURNAL OF CANCER
- Modulating inflammation for cancer therapy
- (2019) Birgit Ritter et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Overexpression of Kynurenine 3-Monooxygenase Correlates with Cancer Malignancy and Predicts Poor Prognosis in Canine Mammary Gland Tumors
- (2019) Yi-Han Chiu et al. Journal of Oncology
- A positive feedback between IDO1 metabolite and COL12A1 via MAPK pathway to promote gastric cancer metastasis
- (2019) Zhen Xiang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Indoleamine-2,3-Dioxygenase in Thyroid Cancer Cells Suppresses Natural Killer Cell Function by Inhibiting NKG2D and NKp46 Expression via STAT Signaling Pathways
- (2019) Arum Park et al. Journal of Clinical Medicine
- Indoleamine 2,3‐dioxygenase and tryptophan 2,3‐dioxygenase expression in HPV infection, SILs, and cervical cancer
- (2019) Paloma Almeida Venancio et al. CANCER CYTOPATHOLOGY
- MYC promotes tryptophan uptake and metabolism by the kynurenine pathway in colon cancer
- (2019) Niranjan Venkateswaran et al. GENES & DEVELOPMENT
- Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
- (2019) Georgina V Long et al. LANCET ONCOLOGY
- Targeting tryptophan catabolic kynurenine pathway enhances antitumor immunity and cytotoxicity in multiple myeloma
- (2019) Arghya Ray et al. LEUKEMIA
- Novel conjugates with dual suppression of glutathione S-transferases and tryptophan-2,3-dioxygenase activities for improving hepatocellular carcinoma therapy
- (2019) Shixian Hua et al. BIOORGANIC CHEMISTRY
- Increased indoleamine 2,3-dioxygenase activity and expression in prostate cancer following targeted immunotherapy
- (2019) Chris D. Zahm et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Targeting the Kynurenine Pathway for the Treatment of Cisplatin-Resistant Lung Cancer
- (2019) Dan J. M. Nguyen et al. MOLECULAR CANCER RESEARCH
- CD4/CD8 + T cells, DC subsets, Foxp3, and IDO expression are predictive indictors of gastric cancer prognosis
- (2019) Fangxuan Li et al. Cancer Medicine
- A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy: locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression
- (2019) Richard Klar et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Tryptophan 2,3-Dioxygenase Expression Identified in Human Hepatocellular Carcinoma Cells and in Intratumoral Pericytes of Most Cancers
- (2019) Delia Hoffmann et al. Cancer Immunology Research
- Indoleamine-2,3-Dioxygenase in Non–Small Cell Lung Cancer
- (2018) Ashley Volaric et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- A Cisplatin-Loaded Immunochemotherapeutic Nanohybrid Bearing Immune Checkpoint Inhibitors for Enhanced Cervical Cancer Therapy
- (2018) Na Wang et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- IDO1 Expression Is Associated With Immune Tolerance and Poor Prognosis in Patients With Surgically Resected Esophageal Cancer
- (2018) Yuki Kiyozumi et al. ANNALS OF SURGERY
- The Impact of Indoleamine 2,3-dioxygenase (IDO) Expression on Stage III Gastric Cancer
- (2018) MASAAKI NISHI et al. ANTICANCER RESEARCH
- Tumor-Repopulating Cells Induce PD-1 Expression in CD8 + T Cells by Transferring Kynurenine and AhR Activation
- (2018) Yuying Liu et al. CANCER CELL
- Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma
- (2018) Zachary J. Brown et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Deptor is a novel target of Wnt/β-catenin/c-Myc and contributes to colorectal cancer cell growth
- (2018) Qingding Wang et al. CANCER RESEARCH
- Ruthenium(ii) arene NSAID complexes: inhibition of cyclooxygenase and antiproliferative activity against cancer cell lines
- (2018) Poulami Mandal et al. DALTON TRANSACTIONS
- Expression of programmed cell death protein 1 (PD-1) and indoleamine 2,3-dioxygenase (IDO) in the tumor microenvironment and in tumor-draining lymph nodes of breast cancer
- (2018) Qian Ye et al. HUMAN PATHOLOGY
- Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors
- (2018) Kristian M. Hargadon et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- 1-L-MT, an IDO inhibitor, prevented colitis-associated cancer by inducing CDC20 inhibition-mediated mitotic death of colon cancer cells
- (2018) Xiuting Liu et al. INTERNATIONAL JOURNAL OF CANCER
- Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women
- (2018) Anne M. Mills et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY
- IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1
- (2018) Erik A. Dill et al. MODERN PATHOLOGY
- Indoleamine 2,3-dioxygenase 1 and overall survival of patients diagnosed with esophageal cancer
- (2018) Ari J. Rosenberg et al. Oncotarget
- Peritumoral endothelial indoleamine 2, 3-dioxygenase expression is an early independent marker of disease relapse in colorectal cancer and is influenced by DNA mismatch repair profile
- (2018) Annabel Meireson et al. Oncotarget
- 1-Methyl-D-tryptophan Reduces Tumor CD133+ cells, Wnt/β-catenin and NF-κβp65 while Enhances Lymphocytes NF-κβ2, STAT3, and STAT4 Pathways in Murine Pancreatic Adenocarcinoma
- (2018) Murad Alahdal et al. Scientific Reports
- High Indoleamine 2,3-Dioxygenase Is Correlated With Microvessel Density and Worse Prognosis in Breast Cancer
- (2018) Lijuan Wei et al. Frontiers in Immunology
- Expression of Indoleamine 2,3-Dioxygenase Induced by IFN-γ and TNF-α as Potential Biomarker of Prostate Cancer Progression
- (2018) Irina Banzola et al. Frontiers in Immunology
- Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas
- (2018) Maud Toulmonde et al. JAMA Oncology
- Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors
- (2018) Asha Nayak-Kapoor et al. Journal for ImmunoTherapy of Cancer
- PD-L1 and IDO Expression in Cervical and Vulvar Invasive and Intraepithelial Squamous Neoplasias: Implications for Combination Immunotherapy
- (2018) Zachary Chinn et al. HISTOPATHOLOGY
- Phase 2 trial of the IDO pathway inhibitor indoximod plus gemcitabine / nab-paclitaxel for the treatment of patients with metastatic pancreas cancer.
- (2018) Nathan Bahary et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2 trial of the IDO pathway inhibitor indoximod plus checkpoint inhibition for the treatment of patients with advanced melanoma.
- (2018) Yousef Zakharia et al. JOURNAL OF CLINICAL ONCOLOGY
- Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
- (2018) Andrea Botticelli et al. Journal of Translational Medicine
- TDO2 Overexpression Is Associated with Cancer Stem Cells and Poor Prognosis in Esophageal Squamous Cell Carcinoma
- (2018) Quoc Thang Pham et al. ONCOLOGY
- Prostaglandin E2 Secreted by Thyroid Cancer Cells Contributes to Immune Escape Through the Suppression of Natural Killer (NK) Cell Cytotoxicity and NK Cell Differentiation
- (2018) Arum Park et al. Frontiers in Immunology
- Durable Clinical Responses and Long-Term Follow-Up of Stage III–IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study—A Brief Research Report
- (2018) Julie Westerlin Kjeldsen et al. Frontiers in Immunology
- Profiling targetable immune checkpoints in osteosarcoma
- (2018) Troy A McEachron et al. OncoImmunology
- Indoximod: An Immunometabolic Adjuvant That Empowers T Cell Activity in Cancer
- (2018) Eric Fox et al. Frontiers in Oncology
- Roles of the immune system in cancer: from tumor initiation to metastatic progression
- (2018) Hugo Gonzalez et al. GENES & DEVELOPMENT
- Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications
- (2018) Martina Mandarano et al. VIRCHOWS ARCHIV
- Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model
- (2017) Xiangjing Meng et al. INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY
- Trace derivatives of kynurenine potently activate the aryl hydrocarbon receptor (AHR)
- (2017) Seung-Hyeon Seok et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- De-novo and acquired resistance to immune checkpoint targeting
- (2017) Nicholas L Syn et al. LANCET ONCOLOGY
- Tryptophan metabolism along the kynurenine and serotonin pathways reveals substantial differences in colon and rectal cancer
- (2017) S. Crotti et al. Metabolomics
- ATIM-29. A PHASE 1 STUDY OF PF-06840003, AN ORAL INDOLE 2,3-DIOXYGENASE 1 (IDO1) INHIBITOR IN PATIENTS WITH MALIGNANT GLIOMAS
- (2017) David Reardon et al. NEURO-ONCOLOGY
- The kynurenine pathway and the brain: Challenges, controversies and promises
- (2017) Robert Schwarcz et al. NEUROPHARMACOLOGY
- Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases
- (2017) Michael D. Lovelace et al. NEUROPHARMACOLOGY
- Activation of the kynurenine pathway predicts poor outcome in patients with clear cell renal cell carcinoma
- (2017) Giuseppe Lucarelli et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- The status of immunosuppression in patients with stage IIIB or IV non-small-cell lung cancer correlates with the clinical characteristics and response to chemotherapy
- (2017) Yuan Wang et al. OncoTargets and Therapy
- INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology
- (2017) Eddy W. Yue et al. ACS Medicinal Chemistry Letters
- The addition of celecoxib improves the antitumor effect of cetuximab in colorectal cancer: role of EGFR-RAS-FOXM1-β-catenin signaling axis
- (2017) Araceli Valverde et al. Oncotarget
- P53 prevent tumor invasion and metastasis by down-regulating IDO in lung cancer
- (2017) Dongfang Tang et al. Oncotarget
- MgAl-layered double hydroxide nanoparticles co-delivering siIDO and Trp2 peptide effectively reduce IDO expression and induce cytotoxic T-lymphocyte responses against melanoma tumor in mice
- (2017) Ling-xiao Zhang et al. Journal of Materials Chemistry B
- Nonsteroidal anti-inflammatory drugs (NSAIDs) and prostate cancer risk: results from the EPICAP study
- (2017) Solene Doat et al. Cancer Medicine
- The immune system in cancer metastasis: friend or foe?
- (2017) Louise M.E. Janssen et al. Journal for ImmunoTherapy of Cancer
- The Tim-3-galectin-9 Secretory Pathway is Involved in the Immune Escape of Human Acute Myeloid Leukemia Cells
- (2017) Isabel Gonçalves Silva et al. EBioMedicine
- Indoleamine 2,3-dioxygenase (IDO) expression and malignant transformation in prostate cancer
- (2017) M. Provenzano et al. JOURNAL OF CLINICAL ONCOLOGY
- Development of simultaneous analysis of tryptophan metabolites in serum and gastric juice - an investigation towards establishing a biomarker test for gastric cancer diagnosis
- (2016) Jong Min Choi et al. BIOMEDICAL CHROMATOGRAPHY
- Aberrant Kynurenine Signaling Modulates DNA Replication Stress Factors and Promotes Genomic Instability in Gliomas
- (2016) April C. L. Bostian et al. CHEMICAL RESEARCH IN TOXICOLOGY
- Analysis of Kynurenine/Tryptophan ratio and expression of IDO1 and 2 mRNA in tumour tissue of cervical cancer patients
- (2016) Jayakumar Hascitha et al. CLINICAL BIOCHEMISTRY
- Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab
- (2016) Jon Bjoern et al. CYTOTHERAPY
- Indoleamine 2,3-dioxygenase and regulatory T cells in acute myeloid leukemia
- (2016) Iman Mansour et al. Hematology
- From inflammation to cancer
- (2016) A. Korniluk et al. IRISH JOURNAL OF MEDICAL SCIENCE
- Sunitinib to upregulate IFNg-STAT1 signaling and to increase indoleamine 2,3-dioxygenase (IDO) expression in renal cell carcinoma (RCC).
- (2016) Eric Jonasch et al. JOURNAL OF CLINICAL ONCOLOGY
- Tryptophan-2,3-dioxygenase is regulated by prostaglandin E2 in malignant glioma via a positive signaling loop involving prostaglandin E receptor-4
- (2016) Katharina Ochs et al. JOURNAL OF NEUROCHEMISTRY
- Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model
- (2016) Mitsuto Hanihara et al. JOURNAL OF NEUROSURGERY
- IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance
- (2016) David H. Munn et al. TRENDS IN IMMUNOLOGY
- Relationship between indoleamine 2,3-dioxygenase activity and lymphatic invasion propensity of colorectal carcinoma
- (2016) Atilla Engin et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Lung cancer-derived galectin-1 contributes to cancer associated fibroblast-mediated cancer progression and immune suppression through TDO2/kynurenine axis
- (2016) Ya-Ling Hsu et al. Oncotarget
- Increased expression of IDO associates with poor postoperative clinical outcome of patients with gastric adenocarcinoma
- (2016) Hao Liu et al. Scientific Reports
- Evolution of the RAG1-RAG2 locus: both proteins came from the same transposon
- (2015) Vladimir V Kapitonov et al. Biology Direct
- A TDO2-AhR Signaling Axis Facilitates Anoikis Resistance and Metastasis in Triple-Negative Breast Cancer
- (2015) Nicholas C. D'Amato et al. CANCER RESEARCH
- Kynurenine Signaling Increases DNA Polymerase Kappa Expression and Promotes Genomic Instability in Glioblastoma Cells
- (2015) April C.L. Bostian et al. CHEMICAL RESEARCH IN TOXICOLOGY
- Low expression of Bin1, along with high expression of IDO in tumor tissue and draining lymph nodes, are predictors of poor prognosis for esophageal squamous cell cancer patients
- (2015) Yunlong Jia et al. INTERNATIONAL JOURNAL OF CANCER
- Association of Aspirin and NSAID Use With Risk of Colorectal Cancer According to Genetic Variants
- (2015) Hongmei Nan et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The kynurenine to tryptophan ratio as a prognostic tool for glioblastoma patients enrolling in immunotherapy
- (2015) Lijie Zhai et al. JOURNAL OF CLINICAL NEUROSCIENCE
- TIM-3/Gal-9 interaction induces IFNγ-dependent IDO1 expression in acute myeloid leukemia blast cells
- (2015) Valentina Folgiero et al. Journal of Hematology & Oncology
- High serum concentration of L-kynurenine predicts unfavorable outcomes in patients with acute myeloid leukemia
- (2015) Ryoko Mabuchi et al. LEUKEMIA & LYMPHOMA
- IMCT-21UPDATES ON PHASE 1B/2 COMBINATION STUDY OF THE IDO PATHWAY IHIBITOR INDOXIMOD WITH TEMOZOLOMIDE FOR ADULT PATIENTS WITH TEMOZOLOMIDE-REFRACTORY PRIMARY MALIGNANT BRAIN TUMORS
- (2015) Yousef Zakharia et al. NEURO-ONCOLOGY
- The aryl hydrocarbon receptor (AhR) mediates resistance to apoptosis induced in breast cancer cells
- (2015) Kanae Bekki et al. PESTICIDE BIOCHEMISTRY AND PHYSIOLOGY
- An Autocrine Cytokine/JAK/STAT-Signaling Induces Kynurenine Synthesis in Multidrug Resistant Human Cancer Cells
- (2015) Ivana Campia et al. PLoS One
- Immune evasion in cancer: Mechanistic basis and therapeutic strategies
- (2015) Dass S. Vinay et al. SEMINARS IN CANCER BIOLOGY
- Helicobacter pyloriand serum kynurenine-tryptophan ratio in patients with colorectal cancer
- (2015) Ayse Basak Engin WORLD JOURNAL OF GASTROENTEROLOGY
- Understanding the role of the kynurenine pathway in human breast cancer immunobiology
- (2015) Benjamin Heng et al. Oncotarget
- Prognostic significance of kynurenine 3-monooxygenase and effects on proliferation, migration and invasion of human hepatocellular carcinoma
- (2015) Haojie Jin et al. Scientific Reports
- Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy
- (2015) A. Holtzhausen et al. Cancer Immunology Research
- Indoleamine-2,3-dioxygenase (IDO) metabolic activity is detrimental for cervical cancer patient survival
- (2015) Debbie M Ferns et al. OncoImmunology
- Improved anti-tumor immunity and efficacy upon combination of the IDO1 inhibitor GDC-0919 with anti-PD-l1 blockade versus anti-PD-l1 alone in preclinical tumor models
- (2015) Jessica Spahn et al. Journal for ImmunoTherapy of Cancer
- IDO Downregulation Induces Sensitivity to Pemetrexed, Gemcitabine, FK866, and Methoxyamine in Human Cancer Cells
- (2015) Saman Maleki Vareki et al. PLoS One
- Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia
- (2015) Valentina Folgiero et al. Oncotarget
- Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR
- (2015) Ulrike M. Litzenburger et al. Oncotarget
- Elevation of MMP-9 and IDO induced by pancreatic cancer cells mediates natural killer cell dysfunction
- (2014) Yun-Peng Peng et al. BMC CANCER
- Peritumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control?
- (2014) I. Chevolet et al. BRITISH JOURNAL OF DERMATOLOGY
- Indoleamine 2,3-dioxygenase promotes peritoneal metastasis of ovarian cancer by inducing an immunosuppressive environment
- (2014) Yuko Tanizaki et al. CANCER SCIENCE
- Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors
- (2014) D. A. Wainwright et al. CLINICAL CANCER RESEARCH
- Indoleamine 2,3-Dioxygenase 1 (IDO1) Is Up-Regulated in Thyroid Carcinoma and Drives the Development of an Immunosuppressant Tumor Microenvironment
- (2014) Sonia Moretti et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- The role of plasma IDO activity as a diagnostic marker of patients with colorectal cancer
- (2014) M. Cavia-Saiz et al. MOLECULAR BIOLOGY REPORTS
- Expression of Indoleamine 2,3-Dioxygenase and Infiltration of FOXP3+ Regulatory T Cells Are Associated with Aggressive Features of Papillary Thyroid Microcarcinoma
- (2014) Han Suk Ryu et al. THYROID
- IDO is highly expressed in breast cancer and breast cancer-derived circulating microvesicles and associated to aggressive types of tumors by in silico analysis
- (2014) M. T. Isla Larrain et al. TUMOR BIOLOGY
- Indoleamine 2,3-dioxygenase expression and activity in patients with hepatitis C virus-induced liver cirrhosis
- (2014) KASHIF ASGHAR et al. Experimental and Therapeutic Medicine
- Tumor Growth Control with IDO-Silencing Salmonella--Letter
- (2013) R. M. Hoffman CANCER RESEARCH
- Galectin-1 promotes lung cancer tumor metastasis by potentiating integrin α6β4 and Notch1/Jagged2 signaling pathway
- (2013) Ya-Ling Hsu et al. CARCINOGENESIS
- The Correlation Between the Subsets of Tumor Infiltrating Memory T Cells and the Expression of Indoleamine 2,3-Dioxygenase in Gastric Cancer
- (2013) Rupeng Zhang et al. DIGESTIVE DISEASES AND SCIENCES
- IDO1 Metabolites Activate β-catenin Signaling to Promote Cancer Cell Proliferation and Colon Tumorigenesis in Mice
- (2013) Ameet I. Thaker et al. GASTROENTEROLOGY
- Human CD14+CTLA-4+regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma
- (2013) Yanmei Han et al. HEPATOLOGY
- Discovery of Tryptanthrin Derivatives as Potent Inhibitors of Indoleamine 2,3-Dioxygenase with Therapeutic Activity in Lewis Lung Cancer (LLC) Tumor-Bearing Mice
- (2013) Shuangshuang Yang et al. JOURNAL OF MEDICINAL CHEMISTRY
- AhR expression is increased in hepatocellular carcinoma
- (2013) Ziyu Liu et al. JOURNAL OF MOLECULAR HISTOLOGY
- Cyclooxygenase-2 (COX-2) Inhibition Constrains Indoleamine 2,3-Dioxygenase 1 (IDO1) Activity in Acute Myeloid Leukaemia Cells
- (2013) Maria Iachininoto et al. MOLECULES
- Expression of Indoleamine 2,3-Dioxygenase and Correlation With Pathological Malignancy in Gliomas
- (2013) Kentaro Mitsuka et al. NEUROSURGERY
- Downregulation of aryl hydrocarbon receptor expression decreases gastric cancer cell growth and invasion
- (2013) XIAO-FEI YIN et al. ONCOLOGY REPORTS
- Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer
- (2013) Ben C. Creelan et al. OncoImmunology
- Role of the Wnt-β-catenin signaling pathway in melanoma-mediated dendritic cell tolerization
- (2013) Alisha Holtzhausen et al. Journal for ImmunoTherapy of Cancer
- Changes in the levels of thioredoxin and indoleamine-2,3-dioxygenase activity in plasma of patients with colorectal cancer treated with chemotherapy
- (2012) Monica Cavia-Saiz et al. Biochemistry and Cell Biology
- Galectin-1 Promotes Lung Cancer Progression and Chemoresistance by Upregulating p38 MAPK, ERK, and Cyclooxygenase-2
- (2012) L.-Y. Chung et al. CLINICAL CANCER RESEARCH
- IDO Expression in Brain Tumors Increases the Recruitment of Regulatory T Cells and Negatively Impacts Survival
- (2012) D. A. Wainwright et al. CLINICAL CANCER RESEARCH
- Prognostic role of indoleamine 2,3-dioxygenase in endometrial carcinoma
- (2012) Renske A. de Jong et al. GYNECOLOGIC ONCOLOGY
- Cancer immunoediting by the innate immune system in the absence of adaptive immunity
- (2012) Timothy O’Sullivan et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Downregulation of indoleamine-2,3-dioxygenase in cervical cancer cells suppresses tumor growth by promoting natural killer cell accumulation
- (2012) NAOTO SATO et al. ONCOLOGY REPORTS
- Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase
- (2012) L. Pilotte et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- (-)-Epigallocatechin gallate inhibits the expression of indoleamine 2,3-dioxygenase in human colorectal cancer cells
- (2012) KENGO OGAWA et al. Oncology Letters
- IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan
- (2012) Richard Metz et al. OncoImmunology
- Three aromatic amino acids in gastric juice as potential biomarkers for gastric malignancies
- (2011) Kai Deng et al. ANALYTICA CHIMICA ACTA
- Upregulated Expression of Indoleamine 2, 3-Dioxygenase in Primary Breast Cancer Correlates with Increase of Infiltrated Regulatory T CellsIn Situand Lymph Node Metastasis
- (2011) Jinpu Yu et al. Clinical & Developmental Immunology
- Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
- (2011) Vinod P Balachandran et al. NATURE MEDICINE
- Indoleamine 2,3-dioxygenase expression predicts impaired survival of invasive cervical cancer patients treated with radical hysterectomy
- (2010) Tomoko Inaba et al. GYNECOLOGIC ONCOLOGY
- Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells
- (2010) A. Curti et al. HAEMATOLOGICA
- COX-2 and PGE2 signaling is essential for the regulation of IDO expression by curcumin in murine bone marrow-derived dendritic cells
- (2010) In Duk Jung et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Expression of indoleamine 2,3-dioxygenase in acute myeloid leukemia and the effect of its inhibition on cultured leukemia blast cells
- (2010) Noura M. El Kholy et al. MEDICAL ONCOLOGY
- An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis
- (2010) F. J. Quintana et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer
- (2009) Aaron S Mansfield et al. BMC CANCER
- Aryl hydrocarbon receptor pathway activation enhances gastric cancer cell invasiveness likely through a c-Jun-dependent induction of matrix metalloproteinase-9
- (2009) Tie-Li Peng et al. BMC CELL BIOLOGY
- Prognostic value of indoleamine 2,3-dioxygenase expression in high grade osteosarcoma
- (2009) Hiroshi Urakawa et al. CLINICAL & EXPERIMENTAL METASTASIS
- Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma
- (2009) Tomoko Inaba et al. GYNECOLOGIC ONCOLOGY
- Indoleamine 2,3-Dioxygenase, an Immunomodulatory Protein, Is Suppressed by (−)-Epigallocatechin-3-gallate via Blocking of γ-Interferon-Induced JAK-PKC-δ-STAT1 Signaling in Human Oral Cancer Cells
- (2009) Chieh-Wen Cheng et al. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
- Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer
- (2009) Yuzo Suzuki et al. LUNG CANCER
- Potential therapeutic significance of increased expression of aryl hydrocarbon receptor in human gastric cancer
- (2009) Tie-Li Peng et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Overexpression of Indoleamine 2,3-Dioxygenase in Human Endometrial Carcinoma Cells Induces Rapid Tumor Growth in a Mouse Xenograft Model
- (2008) N. Yoshida et al. CLINICAL CANCER RESEARCH
- Inverse Correlation between Tumoral Indoleamine 2,3-Dioxygenase Expression and Tumor-Infiltrating Lymphocytes in Endometrial Cancer: Its Association with Disease Progression and Survival
- (2008) K. Ino et al. CLINICAL CANCER RESEARCH
- Prognostic Effect of Epithelial and Stromal Lymphocyte Infiltration in Non-Small Cell Lung Cancer
- (2008) K. I. Al-Shibli et al. CLINICAL CANCER RESEARCH
- High expression of indoleamine 2,3-dioxygenase gene in prostate cancer
- (2008) Chantal Feder-Mengus et al. EUROPEAN JOURNAL OF CANCER
- High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome
- (2008) M. E.D. Chamuleau et al. HAEMATOLOGICA
- Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma
- (2008) Ke Pan et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- The Immune Tolerance of Cancer is Mediated by IDO That is Inhibited by COX-2 Inhibitors Through Regulatory T Cells
- (2008) Sung Yong Lee et al. JOURNAL OF IMMUNOTHERAPY
- Expression of Indoleamine 2,3-Dioxygenase in Metastatic Pancreatic Ductal Adenocarcinoma Recruits Regulatory T Cells to Avoid Immune Detection
- (2008) Agnes Witkiewicz et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients’ sera by HPLC and is inducible by IFN-γ
- (2008) Selim Corm et al. LEUKEMIA RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now